4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Xuanzhu Biopharmaceutical Co., Ltd. (2575) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Beijing, China with about 344 employees. Its market capitalization is roughly HK$5 billion. In the fiscal year ended 2025-12-31, 2575 reported CNY 52M in revenue and (CNY 246M) in net income.
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China.
Interactive charts & full statements → Open the 2575 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | CNY 52M | — |
| Gross Profit | CNY 33M | — |
| Operating Income (EBIT) | (CNY 217M) | (CNY 558M) |
| Net Income | (CNY 246M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | CNY 1.6B | — |
| Total Liabilities | CNY 270M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2575 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms